Dedifferentiation of B-lymphoblastic leukemia/lymphoma with t(9;22) BCR::ABL1 to an undifferentiated neoplasm with strong keratin expression in a patient receiving blinatumomab

Dedifferentiation of B-lymphoblastic leukemia/lymphoma with t(9;22) BCR::ABL1 to an undifferentiated neoplasm with strong keratin expression in a patient receiving blinatumomab

Objectives: Lineage switch in patients with B-ALL treated with blinatumomab has been previously reported. We present a case of blinatumomab-treated B-ALL with t(9;22)(q34.1;q11.2) (Ph + B-ALL) relapsing as a keratin-positive undifferentiated neoplasm with lack of B-cell, T-cell, or definitive myeloi...

Full description

Bibliographic Details
Main Authors: Krasimira A. Rozenova, Anja C. Roden, Christopher Hartley, Jess F. Peterson, Gregory E. Otteson, Aref Al-Kali, Harry E. Fuentes Bayne, Mithun V. Shah, Mrinal S. Patnaik, Rebecca L. King, Daniel P. Larson
Format: Article
Language:English
Published: Elsevier 2023-03-01
Series:Human Pathology Reports
Subjects:
B-Lymphoblastic Leukemia
Lymphoma
BCR
ABL1 fusion
Blinatumomab
Online Access:http://www.sciencedirect.com/science/article/pii/S2772736X22001001

Similar Items

Similar Items